Neumora Therapeutics (NMRA) News Today $9.74 +0.05 (+0.52%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Head-To-Head Analysis: Neumora Therapeutics (NMRA) & The CompetitionNovember 23 at 3:57 AM | americanbankingnews.comNeumora Therapeutics' (NMRA) "Outperform" Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research note on Friday.November 22 at 12:20 PM | marketbeat.comContrasting Neumora Therapeutics (NMRA) and Its CompetitorsNovember 22 at 4:49 AM | americanbankingnews.comNeumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | insidermonkey.comNeumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To ExplodeNovember 19, 2024 | msn.comResearch Analysts Offer Predictions for NMRA FY2024 EarningsNovember 17, 2024 | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average Target Price from BrokeragesNovember 16, 2024 | americanbankingnews.comHC Wainwright Issues Pessimistic Outlook for NMRA EarningsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings estimates for Neumora Therapeutics in a research note issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings pNovember 15, 2024 | marketbeat.comFY2024 EPS Estimate for Neumora Therapeutics Cut by AnalystNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Investment analysts at William Blair reduced their FY2024 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a report released on Tuesday, November 12th. William Blair analyst M. Minter now forecasts that the company wNovember 15, 2024 | marketbeat.comThis biotech’s stock could double if its treatment for major depressive disorder succeeds, says MizuhoNovember 14, 2024 | marketwatch.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | msn.comNeumora Therapeutics Reports Q3 2024 Financial ResultsNovember 14, 2024 | markets.businessinsider.comNeumora Therapeutics (NASDAQ:NMRA) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPSNeumora Therapeutics (NASDAQ:NMRA - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.07). During the same period last year, the business posted ($1.14) EPS.November 13, 2024 | marketbeat.comNeumora Therapeutics' (NMRA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday.November 13, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by AnalystsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating onNovember 13, 2024 | marketbeat.comNeumora Therapeutics, Inc.: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | finanznachrichten.deNeumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comMizuho Securities Remains a Buy on Neumora Therapeutics, Inc. (NMRA)November 12, 2024 | markets.businessinsider.comNeumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comJP Morgan Downgrades Neumora Therapeutics (NMRA)November 6, 2024 | msn.comCautious Hold on Neumora Therapeutics Amid Uncertainty in KOASTAL-1 Trial OutcomesNovember 6, 2024 | markets.businessinsider.comNeumora Therapeutics to Participate in Upcoming Conferences in NovemberNovember 6, 2024 | globenewswire.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down - Here's What HappenedNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down - Should You Sell?November 5, 2024 | marketbeat.comNeumora Therapeutics (NMRA) to Release Earnings on TuesdayNeumora Therapeutics (NASDAQ:NMRA) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=641761)November 5, 2024 | marketbeat.comAuour Investments LLC Purchases New Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Auour Investments LLC acquired a new position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 250,000 shares of the coNovember 5, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Downgraded to "Neutral" Rating by JPMorgan Chase & Co.JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their price target for the stock from $18.00 to $15.00 in a research report on Tuesday.November 5, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5% - Time to Sell?Neumora Therapeutics (NASDAQ:NMRA) Trading Down 4.5% - Here's WhyOctober 25, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sees Large Volume Increase - Still a Buy?Neumora Therapeutics (NASDAQ:NMRA) Sees Unusually-High Trading Volume - What's Next?October 23, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider SellingNeumora Therapeutics (NASDAQ:NMRA) Shares Gap Down After Insider SellingOctober 21, 2024 | marketbeat.comSG Americas Securities LLC Lowers Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)SG Americas Securities LLC decreased its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 62.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,581 shares of the company's stock after selling 36,026 shares during tOctober 21, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Director Matthew K. Fust Sells 14,049 SharesOctober 19, 2024 | insidertrades.comNeumora Therapeutics (NASDAQ:NMRA) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Friday.October 18, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Sees Unusually-High Trading Volume - Should You Buy?Neumora Therapeutics (NASDAQ:NMRA) Sees Strong Trading Volume - Still a Buy?October 16, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company grew its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 79.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 111,8October 13, 2024 | marketbeat.comInsider Selling: Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells 5,563 Shares of StockOctober 12, 2024 | insidertrades.comStifel Nicolaus Remains a Buy on Neumora Therapeutics, Inc. (NMRA)October 12, 2024 | markets.businessinsider.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Robert A. Lenz Sells 5,563 SharesNeumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) insider Robert A. Lenz sold 5,563 shares of the firm's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares in the company, valued at $4,847,719.66. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.October 11, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading 6.6% Higher - Still a Buy?Neumora Therapeutics (NASDAQ:NMRA) Trading 6.6% Higher - Should You Buy?October 10, 2024 | marketbeat.comStrong Buy Rating for Neumora Therapeutics Amid Promising Navacaprant Trials and Market PotentialOctober 9, 2024 | markets.businessinsider.comNeumora Therapeutics Share Price (NMRA.US)October 7, 2024 | lse.co.ukMarshall Wace LLP Invests $1.32 Million in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Marshall Wace LLP bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 134,545 shares of the company's stock, valued at approximately $1,323,000October 7, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Trading 7.5% Higher - Still a Buy?Neumora Therapeutics (NASDAQ:NMRA) Trading 7.5% Higher - Here's WhyOctober 4, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) to Post Q3 2024 Earnings of ($0.33) Per Share, HC Wainwright ForecastsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - HC Wainwright issued their Q3 2024 earnings estimates for shares of Neumora Therapeutics in a note issued to investors on Tuesday, October 1st. HC Wainwright analyst D. Tsao forecasts that the company will earn ($0.33) per share for the quaOctober 3, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth PlansOctober 2, 2024 | uk.finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Neumora Therapeutics (NMRA) with Buy RecommendationOctober 2, 2024 | msn.comBuy Rating Affirmed for Neumora Therapeutics on Navacaprant’s Potential in MDD TreatmentOctober 2, 2024 | markets.businessinsider.comLogos Global Management LP Reduces Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Logos Global Management LP cut its holdings in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 21.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 300,000 shares of the company's stock after selliOctober 1, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Coverage Initiated at HC WainwrightHC Wainwright assumed coverage on shares of Neumora Therapeutics in a report on Tuesday. They set a "buy" rating and a $30.00 price objective on the stock.October 1, 2024 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Down 3.1% Neumora Therapeutics (NASDAQ:NMRA) Shares Down 3.1%September 24, 2024 | marketbeat.comLogos Global Management LP Has $2.95 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Logos Global Management LP reduced its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 21.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,000 shares of the company's stock afterSeptember 24, 2024 | marketbeat.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼-0.070.50▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼93▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Halozyme Therapeutics News Today Krystal Biotech News Today ADMA Biologics News Today Arcellx News Today CRISPR Therapeutics News Today Immunovant News Today ImmunityBio News Today Denali Therapeutics News Today Kymera Therapeutics News Today Vericel News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts